Our Pipeline

We develop a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease. Skyhawk’s portfolio includes both internal and partnered programs across neurodegenerative, oncology, neuromuscular, rare and other disease types. Many of our programs are against targets formerly considered “undruggable” for traditional protein-targeting mechanisms.